Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Chicago Comer Children's Hospital, 5839 S. Maryland Ave, MC4065, Chicago, IL 60637, USA.
Expert Rev Clin Immunol. 2010 Jan;6(1):47-54. doi: 10.1586/eci.09.70.
Probiotics have had many applications in the past few years, and inflammatory conditions of the GI tract--including chronic disorders such as inflammatory bowel disease (IBD)--have received the most attention by investigators. In fact, the experimental basis to expect clinical efficacy of probiotics in IBD is quite robust. In spite of this however, only minimal evidence of benefit by any probiotic is currently available in Crohn's disease, either in adult or in pediatric populations. In ulcerative colitis, on the other hand, several probiotic formulations and especially the proprietary preparation VSL#3 (a high-concentration mixture) have been found effective as adjuvant therapy, both in inducing and maintaining remission.
益生菌在过去几年中有许多应用,胃肠道的炎症性疾病——包括炎症性肠病(IBD)等慢性疾病——受到了研究人员的最多关注。事实上,有充分的实验依据表明益生菌对 IBD 具有临床疗效。然而,尽管如此,目前在成人和儿童克罗恩病患者中,任何益生菌的益处都仅有极少的证据。另一方面,在溃疡性结肠炎中,已经发现几种益生菌制剂,特别是专有的 VSL#3 制剂(高浓度混合物)作为辅助治疗有效,无论是在诱导缓解还是维持缓解方面。